Leuthner Brian A 4

4 · Edge Therapeutics, Inc. · Filed Mar 18, 2019

Form 4

Period: 2019-03-15

Chief Executive Officer

Transactions

Exercise/Conversion
Common Stock
2019-03-15+169,032→ 239,268 total
Exercise/Conversion
Restricted Stock Units
2019-03-15−169,032→ 0 total
→ Common Stock (169,032 underlying)

Holdings

Footnotes (7)

[F1]Vesting of RSUs granted to the Reporting Person on August 14, 2018.
[F2]Reflects periodic contributions to the issuer's common stock fund in the issuer's 401(K) Plan as of December 28, 2018. This amendment is being filed to include these shares of the issuer's common stock that were omitted in the prior report.
[F3]The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed as an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
[F4]The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed as an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
[F5]Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit.
[F6]These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria.
[F7]Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest.

Documents

2 files